Viral approaches to cancer gene therapy

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 3, 2002, Pages 369-378

  Hale, S J ^a   Green, N K ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Adenoviruses; Cancer; Cancer gene therapy; Gene delivery; Gene therapy; Retroviruses; Viral vectors; Viruses

Indexed keywords

ACICLOVIR; ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; CYTOKINE RECEPTOR; CYTOSINE DEAMINASE; DNA TOPOISOMERASE INHIBITOR; ENDOSTATIN; ETOPOSIDE; FOCAL ADHESION KINASE; GAMMA INTERFERON; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GREEN FLUORESCENT PROTEIN; GYRASE INHIBITOR; HYBRID PROTEIN; INTERLEUKIN 12; INTERLEUKIN 2; LENTIVIRUS VECTOR; PRODRUG; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; RETROVIRUS VECTOR; THYMIDINE KINASE; TOPOTECAN; TRASTUZUMAB; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VIRUS DNA; VIRUS ENZYME; VIRUS GLYCOPROTEIN;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER; CARCINOGENESIS; CONTROLLED STUDY; DNA VECTOR; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; FEMALE; GENE TARGETING; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; REVIEW; SAFETY; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

EID: 0036125241     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.3.369     Document Type: Review

References (46)

1. Inhibition of potentially lethal DNA damage repair in human tumor cells by β-lapachone, an activator of topoisomerase I
2. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitortopotecan (SK&F 104864)
3. Identification of a p53-dependent negative response element in the bcl-2 gene
4. Expression of growth factor receptors, the focal adhesion kinase, and other tyrosine kinases in human soft tissue tumors
5. Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products
6. Construction of adenovirus vectors through Cre-lox recombination
7. Gene therapy - Promises, problems and prospects
8. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-lengthdystrophin and β-galactosidase
9. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons
10. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig
11. Antigenic determinants of adenovirus capsids. II. Homogeneity of hexons, and accessibility of their determinants, in the virion
12. A helper-independent adenovirus vector with E1, E3, and fiber deleted: Structure and infectivity of fiberless particles
13. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver
14. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5
15. Adenovirus Type 5 fiber knob binds to MHC class I α2 domain at the surface of human epithelial and B lymphoblastoid cells
16. 5 promote adenovirus internalisation but not virus attachment
17. The 'adenobody' approach to viral targeting: Specific and enhanced adenoviral gene delivery
18. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105)
19. Ablating adenovirus Type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generates an endothelial cell-selective adenovirus
20. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies
21. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: What have we learned?
22. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
23. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus
24. Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus
25. Generation of high-titer pseudotyped retroviral vectors with very broad host range
26. Sheep pulmonary adenomatosis: A unique model of retrovirus-associated lung cancer
27. Evidence for a protein related immunologically to the jaagsiekte sheep retrovirus in some human lung tumours
28. Lentiviral vectors: Turning a deadly foe into a therapeutic agent
29. Active nuclear import of human immunodeficiency virus Type 1 preintegration complexes
30. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells
31. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
32. Adeno-associated virus vectors transduce primary cells much less efficiently than immortalized cells
33. Gene therapy against an experimental glioma using adeno-associated virus vectors
34. Epstein-Barr virus vectors for the treatment of Epstein-Barr virus-associated cancers
35. Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells
36. An Epstein-Barr virus transcript from a latently infected, growth-transformed B-cell line encodes a highly repetitive polypeptide
37. Studies on reovirus receptors of L cells: Virus binding characteristics and comparison with reovirus receptors of erythrocytes
38. A comparison of gene transfer methods in human dendritic cells
39. Targeted gene delivery by tropism modified adenoviral vectors
40. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies
41. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector
42. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a Phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial
43. Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo
44. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture
45. Genetically engineered HSV in the treatment of glioma: A review
46. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors